Cedar Clinical Research hosts Phase III investigative therapy for schizophrenia
TORONTO, ONTARIO, 13. September 2021 / (CSE: NM | OTCQB: NVMDF | FWB: HN2) (“Novamind” or the “Company”), a leading mental health company specializing in psychedelic medicine, is pleased to announce that its wholly owned subsidiary Cedar Clinical Research (“CCR”) as a research location for one of Karuna Therapeutics, Inc. (“Karuna”) sponsored clinical trial was selected. Karuna is a Biopharmaceutical company specializing in neuroscience that conducts clinical trials.
The phase III study with the title “An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients with Schizophrenia (EMERGENT-5)” serves to evaluate the investigational drug KarXT in the treatment of Schizophrenia, a serious and potentially debilitating condition that affects around 20 million people worldwide.1
“The antipsychotic drugs currently available are inadequate for too many people with schizophrenia, leaving them with either severely debilitating symptoms or serious side effects such as sedation, weight gain and involuntary Movement patterns suffer, “explains Dr. Reid Robison, Novamind’s Chief Medical Officer and Principal Investigator at CCR. “We need urgently more innovations in this area and I hope for ingredients like KarXT that a novel effect on the brain unfold and potential for a better efficacy and side effect profile bergon.”
The Novamind subsidiary CCR specializes in conducting clinical studies for psychedelics and other innovative therapies. CCR’s research sites are located in Novamind’s Cedar Psychiatry Care Centers, making it easy to recruit large patient populations and giving patients access to innovative, research-stage treatments possiblet. For the year 2021, Cedar Psychiatry expects 65,000 clinic visits, which is a Plus of 225 percent. CCR stands currently under contract for eight clinical studies, using his expertise in the areas of study design, patient recruitment and patient management. CCR has a long track record of working with leading drug development companies, nonprofits, and research institutions, including with Merck & Co., Bionomics, the Ketamine Research Foundation, and the University of Texas in Austin worked together.
„Novamind also lays its emphasis continues to focus on psychedelic medicine, but also offers therapies and carries out innovative research on all aspects mental health, ”explains CEO and Director Yaron Conforti. “It is important to us to respond to the different needs of our customers and to offer them access to the most innovative treatment methods. After all, there is no one-size-fits-all solution to tackling the mental health crisis in society. “
Further information about the phase III study EMERGENT-5 in cooperation with CCR can be found here Link.
Novamind is a leader in mental health, providing safe access to psychedelic medicines through a network of clinics and clinical research sites. Novamind is a provider of ketamine-based psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics. The company also operates Cedar Clinical Research, a contract research organization specializing in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind improves mental well-being and accompanies people throughout their healing process, see novamind.ca.
Yaron Conforti, CEO & Director
Tel: +1 (647) 953 9512
Samantha DeLenardo, VP, Communications
E-mail: [email protected]
Bill Mitoulas, Investor Relations
E-mail: [email protected]
This press release containsAccording to forward-looking statements. All statements in this release that are not based on historical facts are forward-looking statements and involve risks and uncertainties. There can be no guarantee that such statements will prove to be truthful. Actual results and future events could differ materially from such statements. Important factors that could cause actual results to differ materially from the company’s expectations, including the risks identified from time to time in the company’s public announcement. Readers are cautioned that forward-looking information is not reliable. The forward-looking statements in this press release are expressly limited by this cautionary note. The forward-looking statements in this press release are current as of the date of this press release. The company is not obliged to these forward-looking statements publicly update or correct it, either due to new information or future events or for any other reason, unless this is expressly required by the applicable laws.
1: GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. (2018). Global, Regional, and National Incidence, Prevalence, and Years Living with Restrictions for 354 Diseases and Injuries in 195 Countries and Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017. The Lancet, 392(10159), 1789-1858. https://doi.org/10.1016/S0140-6736(18)32279-7
The source language (usually English) in which the original text is published is the official, authorized and legally valid version. This translation is included for better understanding. The German version can be shortened or summarized. No responsibility or liability is assumed for the content, correctness, appropriateness or accuracy of this translation. From the translator’s point of view, the message does not constitute a buy or sell recommendation! Please note the original English message on www.sedar.com, www.sec.gov, www.asx.com.au/ or on the company website!